These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30828023)

  • 21. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.
    de Lange ECM; van den Brink W; Yamamoto Y; de Witte WEA; Wong YC
    Expert Opin Drug Discov; 2017 Dec; 12(12):1207-1218. PubMed ID: 28933618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
    Varma MV; El-Kattan AF
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strain-Dependent Variability of Early Discovery Small Molecule Pharmacokinetics in Mice: Does Strain Matter?
    Barr JT; Tran TB; Rock BM; Wahlstrom JL; Dahal UP
    Drug Metab Dispos; 2020 Aug; 48(8):613-621. PubMed ID: 32474442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and opportunities with modelling and simulation in drug discovery and drug development.
    Lavé T; Parrott N; Grimm HP; Fleury A; Reddy M
    Xenobiotica; 2007; 37(10-11):1295-310. PubMed ID: 17968746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In silico prediction models of the induction of drug-metabolizing enzymes for drug discovery].
    Yoshinari K; Nagai M
    Nihon Yakurigaku Zasshi; 2019; 153(4):186-191. PubMed ID: 30971659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.
    Baneyx G; Fukushima Y; Parrott N
    Future Med Chem; 2012 Apr; 4(5):681-93. PubMed ID: 22458685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
    Bohnert T; Patel A; Templeton I; Chen Y; Lu C; Lai G; Leung L; Tse S; Einolf HJ; Wang YH; Sinz M; Stearns R; Walsky R; Geng W; Sudsakorn S; Moore D; He L; Wahlstrom J; Keirns J; Narayanan R; Lang D; Yang X;
    Drug Metab Dispos; 2016 Aug; 44(8):1399-423. PubMed ID: 27052879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
    Varma MV; Steyn SJ; Allerton C; El-Kattan AF
    Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.